acquired
Stage
1
Investors
About
Orchard Therapeutics develops and commercializes gene therapies for rare immunological and neurological disorders. The company was publicly traded (NSDQ:ORTX) and was acquired by Kyowa Kirin for approximately $0.5B.
Explore Orchard Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.